The FDA’s surprise refusal to even review Moderna’s mRNA flu vaccine is sending a chill through biotech: Companies are openly ...

In an interview, Moderna President Stephen Hoge took questions on an FDA decision on the biotech's mRNA flu vaccine, as well ...

Centivax, Inc., a clinical-stage biotechnology company engineering vaccines and therapies for durable, universal protection ...

IO Biotech presents preclinical data supporting dual-antigen and TGF-β-targeted vaccines for enhancing anti-tumor immunity at AACR 2025. IO Biotech presented new preclinical data at the AACR Annual ...

The Food and Drug Administration has refused to review an application from the biotech company Moderna to approve its mRNA-based flu vaccine. The agency’s decision, which Moderna announced in a press ...

Moderna has pulled the filing for FDA approval of its flu/COVID combination vaccine. The biotech plans to resubmit later this year with the phase 3 flu vaccine efficacy data the agency wants to see.

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...

Zhengye Biotechnology Holding Limited (Nasdaq: ZYBT) (the “Company” or “Zhengye”), a veterinary vaccine manufacturer that ...

The move is further in line with HHS Secretary Kennedy's anti-vaccine policies ...

In an era of escalating biological threats, from weaponized pathogens to evolving viruses like Mpox, small U.S. biotechs are stepping up to bolster military readiness and national security.

DIFF Biotech’s nasal spray influenza vaccine, DIFF-flu receives China NMPA approval: Hangzhou, China Wednesday, February 11, 2026, 15:00 Hrs [IST] Zhejiang Difference Biological ...

ATHENS, Ga. & SAN JOSE, Calif.--(BUSINESS WIRE)--Blue Lake Biotechnology, Inc., a clinical-stage intranasal vaccine company developing parainfluenza virus 5 (PIV5)-vectored vaccines that harness the ...